APO-Bortezomib bortezomib 3.5mg powder for injection vial

Country: Australia

Bahasa: Inggeris

Sumber: Department of Health (Therapeutic Goods Administration)

Bahan aktif:

bortezomib, Quantity: 3.5 mg

Boleh didapati daripada:

Arrotex Pharmaceuticals Pty Ltd

INN (Nama Antarabangsa):

Bortezomib

Borang farmaseutikal:

Injection, powder for

Komposisi:

Excipient Ingredients: mannitol

Laluan pentadbiran:

Subcutaneous, Intravenous

Unit dalam pakej:

1

Jenis preskripsi:

(S4) Prescription Only Medicine

Tanda-tanda terapeutik:

Bortezomib, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,Bortezomib, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,Bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy and who have progressive disease.

Ringkasan produk:

Visual Identification: White to off-white powder; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Status kebenaran:

Licence status A

Tarikh kebenaran:

2015-07-22